Objective: The Hepatitis C Virus (HCV) is a RNA-virus of the Flavivirus family that infects the liver causing cirrhosis, liver failure, and hepatocellular carcinoma, after a few years. The aim of this retrospective study was to analyze the efficacy and safety of sofosbuvir-based therapy in Sardinian patients for the treatment of HCV infections.
Patients and Methods: Ninety-six patients were treated during the study period. The genotype and plasma levels of the virus were determined with the instruments available at the internal analysis laboratory within the University Hospital of Sassari (Sassari, Italy).
Results: The results obtained demonstrate the excellent tolerability and good efficacy of sofosbuvir-based therapy in fighting against HCV infections.
Discussion: The analysis of the results highlighted the therapeutic innovation brought by the second generation of direct-acting antiviral (DAA) agents witchers, with less side effects, as well as the possibility of receiving exclusively oral therapy, also allowing high adherence to the therapy.